The stock of Heat Biologics, Inc. (NASDAQ:HTBX) is now priced at $2.11 and the shares are -0.06 points down or -2.76% lower compared to its previous closing price of $2.17. HTBX shares have a float of 75.53 million and although its performance was 1.44% over the week, it’s one to watch. It means the stock’s downside potential is -100% with the HTBX share price recently placing at $2.07 to $2.14. However, some brokerage firms have priced the stock below the average, including one that has called $2.5.
The shorts are climbing into the Heat Biologics, Inc. stock, with the latest data on short interest released on July 15, 2020, showing that short interest numbers in the HTBX shares have risen. Short interest in the stock represents just 2.86% of its float, but the volume has raised by 576469. The volume of shorted shares rised to 2.157 million from 1.581 million shares over the last two weeks. The average intraday trading volume has been 21.658 million shares, which means that days to cover moved to roughly 1.
In the last trading session, Heat Biologics, Inc. (NASDAQ:HTBX) raised by $0.03 over the week and gained $0.83 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $4.3. The stock recorded its established 52-week high on 07/21/20.
Since 02/27/20, the stock has traded to a low of $0.19 at 982.05%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge. The stock has a beta allocation of 0.69. Being above 1 means that the stock’s volatility is higher than the market and traders are keenly watching it.
Looking at current readings, Heat Biologics, Inc.’s two-week RSI is 54.34. This suggests that the stock is neutral at the moment and that HTBX shares’ price movement remains stable. The stochastic readings are equally revealing at 14.43% meaning the HTBX share price is currently in overbought territory.
The technical chart shows that the HTBX stock will likely settle at between $2.14 and $2.18 per share. However, if the stock dips below $2.07, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $2.04.
Currently, the stock is trading in the red of MACD, with a reading of -0.03. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.
Analysts at Maxim Group assigned HTBX a rating of Buy in their intiating review released on June 20. Noble Financial analysts see the stock as a Buy with a target price of $16 in a flash note released to investors on January 08 initiating covering the stock. H.C. Wainwright analysts see the stock as Buy when the analysts initiated the share price coverage on May 26, placing it at $13.
The average rating for the HTBX equity is 2 and is currently gathering a bullish momentum. Of 3 analysts tracking Heat Biologics, Inc. polled by Reuters, 0 rated HTBX as a hold. The remaining 3 analysts were split evenly. However, the split wasn’t equal as a majority (3) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.